MAPT and Alzheimer disease: Studies have associated lower levels of insulin and IGF1 with AD pathologies such as accelerated tau hyperphosphorylation [42,43,44], showing that an impairment of the insulin/IGF/mTOR signaling pathway can be linked to AD in the general population as well.